$DMRA News

Wedbush Maintains Outperform on Damora Therapeutics, Raises Price Target to $40

Jefferies Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $50

HC Wainwright & Co. Reiterates Buy on Damora Therapeutics, Maintains $45 Price Target

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $35 Price Target

HC Wainwright & Co. Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $45

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wedbush Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $35

Damora Therapeutics: Well-Funded Moonshot For CALR Mutations

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Damora Therapeutics Says On Track For First Regulatory Submission For DMR-001 In Mid-2026

Damora Therapeutics Q1 EPS $(0.62) Misses $(0.40) Estimate

What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For Shareholders

Assessing Damora Therapeutics (DMRA) Valuation After CFO Transition And Recent Share Price Momentum

Damora Therapeutics CFO Lori Firmani Steps Down, Effective May 1

RBC Capital Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $40

What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?

How Much Upside is Left in DAMORA THERAPEU (DMRA)? Wall Street Analysts Think 73.1%

Damora Therapeutics (DMRA) Overhauls Leadership: Is Its Capital Strategy About To Quietly Shift?

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)